OTCMKTS:DTCFF Defence Therapeutics (DTCFF) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free DTCFF Stock Alerts $0.90 -0.06 (-6.22%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$0.90▼$0.9050-Day Range$0.90▼$1.4952-Week Range$0.90▼$3.19Volume100 shsAverage Volume407 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get Defence Therapeutics alerts: Email Address Ad Crypto Swap ProfitsHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Defence Therapeutics Stock (OTCMKTS:DTCFF)Defence Therapeutics Inc. engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.Read More DTCFF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DTCFF Stock News HeadlinesApril 17, 2024 | finance.yahoo.comDefence Therapeutics Signs with German Based FMS Consult GmbH for Financing Strategy to Support Defence Pipeline GrowthFebruary 29, 2024 | finanznachrichten.deDefence Therapeutics Inc.: Defence Announces Peer-Reviewed Publication on Accum-E7 Anti-Cancer Vaccine in Cancer Science Journal and Financing UpdateApril 25, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.January 30, 2024 | finance.yahoo.comDefence Therapeutics Completes 1st Tranche of FinancingJanuary 19, 2024 | finance.yahoo.comDefence FinancingJanuary 13, 2024 | finance.yahoo.comDefence Begins Trading on the OTCQB and Arranges FinancingJanuary 10, 2024 | morningstar.comDefence Therapeutics Inc DTCFFDecember 12, 2023 | finance.yahoo.comRETRANSMISSION: Defence Receives FDA Approval for Phase I Clinical Trial Targeting Solid Cancer Tumors with AccuTOX(R)April 25, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.December 11, 2023 | finance.yahoo.comDefence Receives FDA Approval for Phase I Clinical Trial Targeting Solid Cancer Tumors with AccuTOX(R)November 14, 2023 | finance.yahoo.comDefence's Successful Submission of an Investigational New Drug (IND) Application for AccuTOX(R) as an Injectable Anticancer Treatment for Solid TumorsNovember 7, 2023 | finance.yahoo.comDefence Therapeutics Key Platform Patent Accepted Broadly Covering Vaccine TechnologyOctober 27, 2023 | finanznachrichten.deDefence Therapeutics Inc.: Defence to Collaborate with Native Ads for Marketing CampaignOctober 26, 2023 | finanznachrichten.deDefence Therapeutics Inc.: Defence to Present Three of Its Leading Products at the Upcoming Festival of Biologics in Basel, SwitzerlandOctober 26, 2023 | finanznachrichten.deDefence Therapeutics Inc.: Defence's Accum(R)-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA VaccinesOctober 25, 2023 | finance.yahoo.comDefence's AccuTOX(R) And Antigen Cross-Presentation: Discovery Leads Towards the Development of a Groundbreaking PlatformOctober 22, 2023 | investing.comDefence Therapeutics Inc (DTC)October 18, 2023 | finance.yahoo.comDefence's Novel Accutox(TM) Continues to Surprise on Results Against CancerOctober 17, 2023 | theglobeandmail.comBristol Myers Squibb Enters the Multi-Billion-Dollar Oncology RaceOctober 17, 2023 | finance.yahoo.comDefence's Delivery of Encapsulated AccuTOX(TM)-Chitosan Nanoparticles Triggers Complete Tumor Regression in Animals with Pre-Established Solid LymphomaOctober 11, 2023 | theglobeandmail.comElli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology RaceOctober 10, 2023 | finance.yahoo.comDefence Announces Peer-reviewed Publication of Its Preclinical Data on Accum(R) as an Anti-Cancer Molecule in the Journal of Cancer ScienceOctober 6, 2023 | finance.yahoo.comDefence to Present Three of Its Leading Products at the Upcoming Festival of Biologics in Basel, SwitzerlandSeptember 28, 2023 | finanznachrichten.deDefence Therapeutics Inc.: Defence's Innovative Therapeutics Featured on Viewpoint with Dennis QuaidSeptember 25, 2023 | finance.yahoo.comDefence's Accum(R)-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA VaccinesSeptember 22, 2023 | finance.yahoo.comDefence to Collaborate with Native Ads for Marketing CampaignSeptember 14, 2023 | yahoo.comSelf-defense classes for women hit the mark in North PortSee More Headlines Receive DTCFF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Defence Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:DTCFF CUSIPN/A CIKN/A Webdefencetherapeutics.com Phone514 947 2272FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Sebastien Plouffe (Age 52)CEO, President & Director Comp: $81.52kMr. Patrick Joseph Meagher C.A. (Age 38)CPA, CA, CPA, CFO & Director Comp: $57.6kDr. Moutih Rafei Ph.D. (Age 42)Chief Scientific Officer & Director Comp: $9.06kDr. Simon Beaudoin (Age 39)Chief Technical Science Officer Ms. Carrie Cesarone (Age 59)Corporate Secretary Key Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors DTCFF Stock Analysis - Frequently Asked Questions How have DTCFF shares performed in 2024? Defence Therapeutics' stock was trading at $1.65 at the beginning of 2024. Since then, DTCFF shares have decreased by 45.2% and is now trading at $0.9049. View the best growth stocks for 2024 here. How do I buy shares of Defence Therapeutics? Shares of DTCFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:DTCFF) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchGreat Crypto BullWeiss RatingsMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Defence Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
